Biotie Therapies
Finans
About Biotie Therapies
Biotie is a specialized drug development company focused on central nervous system and inflammatory diseases. It has several innovative small molecule and biological drug candidates at different stages of clinical development. Biotie's products address diseases with high unmet medical need and significant market potential, including addiction and a broad range of inflammatory conditions such as rheumatoid arthritis and chronic obstructive pulmonary disease (COPD). The most advanced product, nalmefene for alcohol dependence, is currently in phase III clinical development by licensing partner H. Lundbeck A/S.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $252.5M
- Funding stage: M&A
- Last round: Post-IPO Equity (Jun 2015)
- Ticker: nasdaq:BITI
- Website: biotie.com
- Phone: +135822748900
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/biotie-therapies-246137 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.